Lilly’s rheumatoid arthritis drug using JAK inhibitors gets positive 2b results
Eli Lilly‘s (NYSE:LLY) rheumatoid arthritis treatment developed by drug developer Incyte (NASDAQ:INCY) using oral janus-associated kinases, or JAK, inhibitors, has produced positive phase 2b results, according to a company statement. The results were presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology. The randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, involved […]